Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Publication of Positive MED2002 Clinical Data

Futura Medical
Posted on: 05 Jan 18

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce the publication of positive data from its Phase II clinical trial of MED2002* in erectile dysfunction (“ED”) in the peer-reviewed Journal of Sexual Medicine.


The article is available at this link: {}


The positive headline results of the Phase II trial were announced in September 2016 and showed that MED2002 has met its primary endpoint in showing a statistically significant improvement in erectile function in men with confirmed ED compared with placebo. The rapid onset of action of MED2002 means that it has the potential to be the world’s fastest-acting treatment for ED.


The Journal of Sexual Medicine article includes further data from the Phase II study including details of positive secondary outcome measures. These show significant improvements with MED2002 in orgasmic function (p=0.012), sexual desire (p<0.0001), intercourse satisfaction (p=0.0055) and overall satisfaction (p=0.001) compared with placebo. These improvements are in standard measures used in the International Index of Erectile Function questionnaire (IIEF).  The IIEF is considered the ‘'gold standard' measure for efficacy assessment in clinical trials of ED. The data includes the result that 70% of participants on average experienced onset of erection within 10 minutes.


James Barder, Futura’s Chief Executive, said:  “The publication of the Phase II clinical data in the leading, peer-reviewed scientific journal in sexual medicine underlines the robustness of our previously reported study and demonstrates the level of scientific interest in MED2002. The article, in the Journal of Sexual Medicine, reinforces our belief that MED2002 has the potential to be the world’s fastest-acting treatment for erectile dysfunction.  MED2002 also has the potential to be a first-line treatment for ED patients who are unable to use existing oral treatments or who are seeking the benefits of greater spontaneity and intimacy through a fast acting treatment that doesn’t require pre-planning.


“We recently began the remaining clinical trial programme for MED2002 with a pharmacokinetic study, to be followed by two Phase III studies, the first of which is expected to begin in the first half of 2018.”


For any further information please contact:



Futura Medical plc


James Barder, Chief Executive


Tel: +44 (0)1483 685 670

mail to:




N+1 Singer (Nominated Adviser and Broker)


Aubrey Powell / Liz Yong


Tel:+44 (0) 20 7496 3000



For media enquiries please contact:





Mark Court / Sophie Wills / Stephanie Watson

Tel: +44 (0)20 7466 5000

Editor's Details

Mike Wood

Last updated on: 05/01/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.